News

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, discuss adapting to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties.

Leveraging an essential, new set of behaviorally informed best practices to break free from the constraints of the Iron Triangle of Clinical Trial Complexity.

Investigational, once-weekly combination shows promise as long-acting oral treatment option for those virologically suppressed with HIV.

Blenrep (belantamab mafodotin) combined with pomalidomide plus dexamethasone showed favorable progression-free survival compared with standard of care in the second-line and later treatment of relapsed or refractory multiple myeloma.

The six steps to designing a successful diversity action plan for a clinical trial protocol.

Why weighing all of the ‘DE&I’ components is critical at site and sponsor levels.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, talk about ways their company has improved efficiency and accuracy in clinical trials for clients such as NCI designated cancer centers.

Despite industry-wide excitement over the involvement of retail pharmacies in clinical research, there is little information currently available on how retail pharmacies are perceived by investigative sites and patients.

Webinar Date/Time: Thu, Mar 28, 2024 12:00 PM EDT

Zilebesiran added to standard of care treatment for mild to moderate hypertension produced a clinically and statistically significant decrease in systolic blood pressure after three months.

Identifying KPIs, benchmarks, key data points, and an actionable plan are all keys to accelerating study start-up cycles.

Elysium Therapeutics’ proprietary O2P is a hydrocodone prodrug for the treatment of moderate-to-severe acute pain.

The FDA previously halted the IOV-LUN-202 trial following reports of a grade 5 serious adverse event that may have been linked to treatment with Iovance Biotherapeutics’ novel tumor infiltrating lymphocyte cell therapy LN-145, which is being evaluated in patients with advanced non–small cell lung cancer.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, provide commentary on current obstacles associated with clinical trials and how their company is addressing them.

While little research on open-cohort designs currently exists, could this design be a solution to challenges currently seen in closed-cohort designs?

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).

Zolgensma (onasemnogene abeparvovec), a one-time gene therapy, showed a clinical benefit for older and heavier patients with spinal muscular atrophy, many of whom were previously treated with another disease-modifying therapy.

With inequalities in palliative care provisions, recent study seeks to create a more equitable, diverse, and inclusive framework based on Patient and Public Involvement.

Data from a pair of Phase III trials indicated a progression-free survival and complete response advantage in favor of Brukinsa in patients with relapsed or refractory chronic lymphocytic leukemia.

Life sciences leaders are overcoming challenges to speed the development, launch, and education of novel medicines for rare diseases.

A study exploring healthcare preference and experience in this population group uncovers new insights and opportunities related to clinical research participation.

With significant race and sex disparities in the area of peripheral artery disease, a study shows that clinical trials often lack representative patient populations.

UCB seeks approval of Bimzelx (bimekizumab-bkzx) for psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.

A framework to understand the different approaches of trial matching solutions and the major operational and workflow challenges that all matching solutions share.

VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

PL9643 ophthalmic solution is a melanocortin agonist with a novel mechanism of action that produced a clinically meaningful and statistically significant reduction in pain associated with dry eye disease.

The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.

Epkinly (epcoritamab-bysp), subcutaneously administered, T-cell engaging, IgG1-bispecific antibody, was previously granted Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory follicular lymphoma.